Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Pituitary Diseases

ClinicalTrials.gov lists 1,012 trials for Pituitary Diseases or a narrower condition beneath it. Ipsen has the most among industry and government lead sponsors, with 35.

MeSH D010900 Nervous System Diseases C10 C19
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 57 Phase 1/2 Phase 1/2 10 Phase 2 Phase 2 119 Phase 2/3 Phase 2/3 19 Phase 3 Phase 3 126 Phase 4 Phase 4 111 Not applicable Not applicable 204 Observational Observational 365 Phase 1 Phase 1 57 Phase 1/2 Phase 1/2 10 Phase 2 Phase 2 119 Phase 2/3 Phase 2/3 19 Phase 3 Phase 3 126 Phase 4 Phase 4 111 Not applicable Not applicable 204 Observational Observational 365

Trials per phase (log scale)

1 more section with rows

73 of the 1,012 trials are tagged with Pituitary Diseases itself; the rest are tagged with a narrower condition beneath it.

Get the Pituitary Diseases report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Pituitary Diseases trials start? (34)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 60

1991: 1 trials (Observational 1) 1993: 3 trials (Observational 3) 1995: 6 trials (Observational 5, Phase 4 1) 1996: 1 trials (Observational 1) 1997: 8 trials (Observational 5, Not applicable 1, Phase 3 2) 1998: 3 trials (Not applicable 1, Phase 4 1, Phase 1 1) 1999: 5 trials (Observational 2, Phase 4 2, Phase 2 1) 2000: 8 trials (Observational 3, Phase 3 2, Phase 2/3 2, Phase 1 1) 2001: 16 trials (Observational 4, Not applicable 4, Phase 4 2, Phase 3 3, Phase 2/3 1, Phase 2 1, Phase 1 1) 2002: 13 trials (Observational 3, Not applicable 2, Phase 4 3, Phase 3 4, Phase 2 1) 2003: 27 trials (Observational 8, Not applicable 2, Phase 4 7, Phase 3 8, Phase 2/3 1, Phase 2 1) 2004: 30 trials (Observational 5, Not applicable 4, Phase 4 6, Phase 3 6, Phase 2 8, Phase 1 1) 2005: 25 trials (Observational 11, Not applicable 3, Phase 4 3, Phase 3 6, Phase 2 2) 2006: 33 trials (Observational 10, Not applicable 2, Phase 4 5, Phase 3 8, Phase 2 6, Phase 1 2) 2007: 36 trials (Observational 14, Not applicable 4, Phase 4 4, Phase 3 7, Phase 2 5, Phase 1 2) 2008: 46 trials (Observational 15, Not applicable 6, Phase 4 7, Phase 3 8, Phase 2/3 2, Phase 2 4, Phase 1/2 2, Phase 1 2) 2009: 29 trials (Observational 8, Not applicable 3, Phase 4 6, Phase 3 5, Phase 2 6, Phase 1 1) 2010: 35 trials (Observational 13, Not applicable 5, Phase 4 1, Phase 3 6, Phase 2/3 2, Phase 2 4, Phase 1 4) 2011: 50 trials (Observational 17, Not applicable 13, Phase 4 3, Phase 3 4, Phase 2 8, Phase 1/2 1, Phase 1 4) 2012: 36 trials (Observational 18, Not applicable 6, Phase 4 3, Phase 3 2, Phase 2 3, Phase 1/2 1, Phase 1 3) 2013: 45 trials (Observational 22, Not applicable 2, Phase 4 8, Phase 3 2, Phase 2 6, Phase 1/2 1, Phase 1 4) 2014: 35 trials (Observational 14, Not applicable 5, Phase 4 6, Phase 3 4, Phase 2/3 2, Phase 2 4) 2015: 49 trials (Observational 14, Not applicable 8, Phase 4 8, Phase 3 8, Phase 2/3 1, Phase 2 5, Phase 1/2 1, Phase 1 4) 2016: 49 trials (Observational 18, Not applicable 16, Phase 4 4, Phase 3 3, Phase 2/3 2, Phase 2 4, Phase 1/2 1, Phase 1 1) 2017: 42 trials (Observational 13, Not applicable 7, Phase 4 4, Phase 3 8, Phase 2/3 1, Phase 2 6, Phase 1/2 1, Phase 1 2) 2018: 42 trials (Observational 14, Not applicable 15, Phase 4 2, Phase 3 2, Phase 2/3 1, Phase 2 5, Phase 1/2 1, Phase 1 2) 2019: 60 trials (Observational 22, Not applicable 17, Phase 4 2, Phase 3 7, Phase 2/3 1, Phase 2 8, Phase 1 3) 2020: 35 trials (Observational 13, Not applicable 15, Phase 3 1, Phase 2/3 1, Phase 2 3, Phase 1 2) 2021: 44 trials (Observational 15, Not applicable 11, Phase 4 7, Phase 3 6, Phase 2 5) 2022: 29 trials (Observational 14, Not applicable 6, Phase 4 3, Phase 2 5, Phase 1 1) 2023: 41 trials (Observational 18, Not applicable 10, Phase 4 5, Phase 3 2, Phase 2/3 1, Phase 2 2, Phase 1/2 1, Phase 1 2) 2024: 47 trials (Observational 15, Not applicable 17, Phase 4 5, Phase 3 1, Phase 2 7, Phase 1 2) 2025: 39 trials (Observational 12, Not applicable 9, Phase 4 2, Phase 3 4, Phase 2/3 1, Phase 2 6, Phase 1 5)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 36
2025 39
2024 47
2023 41
2022 29
2021 44
2020 35
2019 60
2018 42
2017 42

Showing 10 of 34 earlier years.

Start your 14-day trial Email me all 34 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 47 trials starting in 2026 and about 44 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 71 trials still running at the 2026-10-09 snapshot; registered median of 27 months across 615 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Pituitary Diseases trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 57
Phase 1/2 10
Phase 2 119
Phase 2/3 19
Phase 3 126
Phase 4 111
Not applicable 204
Observational 365
Expanded access 1

How many Pituitary Diseases trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 26
Recruiting 109
Enrolling by invitation 8
Active, not recruiting 22
Completed 566

Showing 5 of 10 statuses.

Start your 14-day trial Email me all 10 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Pituitary Diseases trials? (7)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Ipsen 35
Novo Nordisk A/S 27
Pfizer 26
Novartis Pharmaceuticals 24
Changchun GeneScience Pharmaceutical Co., Ltd. 15

Showing 5 of 7 sponsors.

Start your 14-day trial Email me all 7 sponsors as a PDF

Which drugs are being tested for Pituitary Diseases? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Pegvisomant 18
Somapacitan 11
Norepinephrine 10
MOD-4023 8

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
somatropin AQ 93
Vasopressins 35
LAR Octreotide 29
Pasireotide s.c. 17
Cabergoline Pill 15

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Pituitary Diseases trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 146 20
Pituitary tumour recurrent 142 5
Cholelithiasis 101 15
Cerebrovascular accident 88 9
Death 74 8

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Pituitary Diseases? (36)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Acquired forms of central diabetes insipidus: Mechanisms of disease. Best practice & research. Clinical endocrinology & metabolism 2020 Yes
Peel-off resection of the pituitary gland for functional pituitary adenomas: pathological significance and impact on pituitary function. Pituitary 2019 Yes
Pituitary Diseases and Bone. Endocrine reviews 2018 Yes
MANAGEMENT OF ENDOCRINE DISEASE: Quality of life tools for the management of pituitary disease. European journal of endocrinology 2017 Yes
The development and validation of the Leiden Bother and Needs Questionnaire for patients with pituitary disease: the LBNQ-Pituitary. Pituitary 2016 Yes

Showing 5 of 36 publications.

Start your 14-day trial Email me all 36 publications as a PDF

Sub-conditions in MeSH (6)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages